Cancer-fighting drugs called bispecific antibodies are having a moment. A growing number are making their way into the clinic, and researchers are developing increasingly elaborate molecules with new capabilities. In the past five years, the number of bispecific antibodies ' which can bind to two targets at the same time ' approved by global regulators has grown from 3 to more than 20, says Christian Klein, who developed drugs at pharmaceutical company Roche in Basel, Switzerland, and is now launching his own biotechnology firm. The drugs generated US$18 billion in sales in 2025, he says. 'Bispecifics have really kind of exploded,' says Paul Carter, who develops antibody therapies at Genentech, a biotechnology company in South San Francisco, California. 'There are more flavours of bispecifics than Ben and Jerry's ice cream.' That success ' as well as advances in protein production and artificial intelligence ' is spurring efforts to create 'multispecific' antibodies that bind to...
learn more
